Accretive Combination Increases Scale, Diversifies Revenue Streams, and Leverages Corporate Overhead and Public Company Costs Better Positions both Companies to Accelerate Growth and Maximize Sharehol ...

Iluzanebart (VGL101), Vigil’s monoclonal antibody program, is not being acquired by Sanofi, and its return to Amgen, the original licensor, and the termination of the exclusive license agreement with ...

Capital One and Discover completed their merger on May 18. Discover what financial professionals say you should do to keep ...

Rising costs and competition are fuelling merger talks across the mutuals sector — and People First Bank is ready to make its ...

The joint resolution to roll back the regulator’s 2024 merger rule now heads to the president for a signature.